Compare Illumina, Inc. (ILMN) vs iShares Core S&P 500 ETF (IVV) Price & Performance

Illumina, Inc.Trade

iShares Core S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

Illumina, Inc. vs iShares Core S&P 500 ETF — how do they compare? Illumina, Inc. trades at $192.36 (market cap $27.94B), while iShares Core S&P 500 ETF trades at $751.73. Which is the better fit depends on your goals.

	ILMN	IVV
Market Cap	$27.94B	—
Sector	Health	Broad Market / Factor
52-Week High	$194.33	$763.10
52-Week Low	$91.00	$624.65
Enterprise Value	$29.33B	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Illumina, Inc.

Illumina (ILMN) trades at $192.53, up 3.15% today, with bullish technical signals and strong fundamental recovery. The stock shows robust profitability with a 19.42% net margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and new executive appointments, reinforcing growth prospects in genomics.

Outlook remains positive driven by sequencing demand and cost control, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is Buy with a $178 target, though the current price exceeds this, suggesting cautious optimism amid execution risks.

iShares Core S&P 500 ETF

IVV, tracking the S&P 500, trades at $745.67, down 0.14% amid technical bearish signals and resistance at the 50-day moving average. The ETF faces valuation concerns with the Shiller CAPE ratio near historic highs. Recent institutional buying by Decker Wealth Management contrasts with broader market caution as earnings season progresses with mixed tech performance.

Outlook hinges on S&P 500 earnings resilience, particularly from tech giants, but overvaluation risks and sector concentration warrant caution. The bearish technical setup suggests near-term pressure, though long-term investors may find value in dollar-cost averaging given the index's historical track record.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ILMN

ARKG and GNOM ETFs offer different genomic bets with varied risk and returns in 2026.24/7 Wall Street · 16 hours agoNeutral Cancer biomarkers market to hit $54.48B by 2032, driven by tech advances and Asia-Pacific growthResearchandmarkets.Com · 4 days agoBullish New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral View details →

IVV

Invesco S&P 500 Equal Weight Consumer Discretionary ETF seen as a Hold, likely underperforming IVV again.Seeking Alpha · 2 days agoNeutral BlackRock's MAXJ ETF offers S&P 500 returns with downside protection but caps gains at 10.6%.24/7 Wall Street · 3 days agoNeutral SPY ETF charges higher fees than its cheaper sibling SPYM with identical S&P 500 exposure.24/7 Wall Street · 4 days agoBearish View details →

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.